Summary: Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved for children as young…
ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved.
Designed and Developed by Ample eBusiness
-
-
Summary : Through the acquisition of Global Blood Therapeutics, Pfizer aims to enhance its presence in rare haematology and particularly sickle cell…
-
Active Agrochemical IngredientAgrochemical Discovery Candidates (New ISO)Flusulfinam
NEW ISO HERBICIDE CANDIDATE PUBLISHED AUGUST 2022 – FLUSULFINAM FROM CHINESE PLAYER QINGDAO KINGAGROOT CHEMICAL
New ISO Candidate Published August 2022 – Flusulfinam: New herbicide candidate from Qingdao Kingagroot Chemical Compound Co., Ltd., China Suflufenam (generic name:…
-
AstraZenecaRegulatoryU.S FDA
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer
Synopsis: Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and…
-
Sanofi and Innovent Biologics have announced a collaboration that will bring innovative medicines to patients in China with difficult-to-treat cancers. Innovent is…
-
Marius PharmaceuticalsRegulatoryU.S FDA
Marius Pharmaceuticals Receives FDA Approval of KYZATREX™, an Oral Testosterone Replacement Therapy
Summary : Marius Pharmaceuticals, a patient-centric healthcare company, today announced the approval of KYZATREX™ (testosterone undecanoate) by the U.S. Food and Drug…
-
Summary: GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission’s (EC) Health Emergency Preparedness and Response…
-
Pharma Science & ResearchRegulatoryU.S FDA
FDA Grants Coherus’ CIMERLITM (Ranibizumab-eqrn) 12 Months of Interchangeability Exclusivity as the First and Only Interchangeable Biosimilar to Lucentis® for all Five Indications.
Synopsis : CIMERLI™ is Coherus’ third FDA-approved product and the first of four new product launches planned by the end of 2023 …
-
Summary: Iconovo has revealed that it has received a grant of $883,800 from the Bill & Melinda Gates Foundation to develop a…
-
Global Market
MHRA Grants Marketing Authorisation for Global Blood Therapeutics’s Oxbryta (Voxelotor)
Summary: Voxelotor is the first medicine in Britain to directly inhibit sickle haemoglobin polymerisation Global Blood Therapeutics (GBT) has announced that the…